CHMP backs BG-12, Aubagio for MS

EMA's CHMP recommended approval of two relapsing-remitting multiple sclerosis (RRMS) therapies on Friday: Tecfidera dimethyl fumarate ( BG-12) from Biogen Idec Inc. (NASDAQ:BIIB) and Aubagio teriflunomide from Sanofi (Euronext:SAN; NYSE:SNY). Biogen Idec said it expects a decision from the European Commission in about two months for Tecfidera, an oral dimethyl fumarate that activates the NF-E2-related factor 2 (Nrf2) pathway. The company added that a decision from FDA for Tecfidera is expected "in the coming days." Biogen Idec was up $1.45 to $178 on Friday. ...